SynthesisNeurosurgical review2025
Incidence of cerebral hyperperfusion syndrome following revascularization surgery in moyamoya patients: a systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moyamoya disease (MMD) is a chronic cerebrovascular disorder marked by the narrowing of the internal carotid artery and the formation of atypical collateral blood vessels. To reduce the risk of ischemic or hemorrhagic events, surgical revascularization is considered the standard treatment. Also, a major postoperative concern is cerebral hyperperfusion syndrome (CHS), which results serious complications such as seizures and intracranial hemorrhage. This systematic review and meta-analysis aimed to evaluate the incidence of CHS in patients with MMD undergoing cerebral revascularization surgery. A comprehensive database search was conducted from the inception until October 6th, 2024 in order to identify the eligible studies that reported sufficient data regarding CHS and its associated complications among MMD patients undergoing cerebral revascularization surgery. A total of 177 articles were screened, and 23 studies consisting of 2083 patients were included in this study. The pooled incidence of CHS was 23% (95% CI: 17–30%), with higher rates in direct revascularization (27%) compared to combined methods (21%). The incidence of postoperative seizures was 8% (95% CI: 5–11%), and hemorrhage was 15% (95% CI: 7–24%). No significant publication bias was detected. This study highlights the incidence of CHS following revascularization procedures. The associated complications, such as seizures and hemorrhage, underscore the need for intensive monitoring. These findings emphasize the importance of personalized surgical planning and optimized diagnostic approaches to improve patient outcomes in CHS management.
Indexed as
Identifiers
41392131What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.